RWAYL — Runway Growth Finance Corp. - 7

Summary of Runway Growth Finance Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Investment Income: $36.7 million, up from $35.1 million in Q2 2025.
• Net Investment Income: $15.7 million, an increase from $13.9 million in Q2 2025.
• Weighted Average Portfolio Risk Rating: Increased to 2.42 from 2.33 in Q2 2025.
• Loan-to-Value Ratio: Increased to 31.4% from 29.6% in Q2 2025.
• Fair Value of Total Investment Portfolio: $946 million, down 7.7% from $1.02 billion in Q2 2025.
• NAV per Share: Decreased to $13.55 from $13.66 in Q2 2025.
• Operating Expenses: $21 million, slightly down from $21.2 million in Q2 2025.
• Net Realized Loss on Investments: $1.3 million, improved from $1.5 million in Q2 2025.
• Spillover Income: Approximately $0.53 per share.
• Debt Portfolio Yield: Increased to 16.8% from 15.4% in Q2 2025.

2. Strategic Updates and Business Highlights

• Completed 11 investments totaling $128.3 million in Q3 2025, focusing on technology, healthcare, and select consumer sectors.
• Announced a definitive merger agreement to acquire SWK Holdings, expected to scale the portfolio by approximately $242 million and enhance investment capabilities in healthcare and life sciences.
• The merger is structured as a NAV for NAV transaction, with an estimated purchase price of $220 million, including cash and stock.
• Focus on portfolio optimization through diversification and smaller position sizes, leveraging the BC Partners Credit ecosystem for broader origination channels.

3. Forward Guidance and Outlook

• Anticipate the SWK acquisition to be accretive to earnings in the first full quarter post-closing, expected in early 2026 due to potential delays from the government shutdown.
• Project mid-single-digit run rate net investment income accretion and improved dividend coverage following the merger.
• Expect normal course of prepayments to continue, with a muted repayment activity anticipated in Q4 2025.

4. Bad News, Challenges, or Points of Concern

• Decrease in Fair Value: The total investment portfolio's fair value decreased by 7.7%, raising concerns about asset performance.
• NAV Decline: NAV per share decreased by 1.9%, indicating potential challenges in maintaining shareholder value.
• Single Loan on Nonaccrual Status: Only one loan (Mingle Healthcare) is on nonaccrual status, but it represents a small portion of the portfolio.
• Competitive Pressures: Noted spread compression in the venture debt space, although less severe than in broader markets.
• Regulatory Delays: Anticipated delays in the SEC approval process for the merger due to the government shutdown.

5. Notable Q&A Insights

• Origination and Repayment Activity: Q4 is expected to see muted repayments compared to Q3, with origination activity continuing through the BC Partners Credit platform.
• Integration of SWK Team: The SWK team will assist in transitioning the portfolio and origination during the integration period.
• Dividend Policy: The Board declared a dividend of $0.33 per share, aligning with anticipated earnings power despite substantial paydowns.
• Loss Drivers: Realized losses were primarily from the equity portfolio, attributed to idiosyncratic issues rather than sector-wide problems.
• PIK Income: Composed of both structured and credit-related PIK, with a focus on maintaining loan-to-value ratios despite accrued PIK.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and challenges faced by Runway Growth Finance as discussed in the Q3 2025 earnings call.